Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of tislelizumab- and/or pamiparib-containing treatments in advanced malignancies
jRCT2031230161Recruiting
- Sponsor
- BeOne Medicines
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Open-label, single-arm trial of tislelizumab and pamiparib in malignant solid tumor and hematopoietic malignancies, sponsored by BeOne Medicines. Primary endpoint: Long-term safety of BeiGene investigational drugs. Started Dec 2022; status: recruiting.
02
Drugs
tislelizumabpamiparib
03
Conditions
malignant solid tumorhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2031230161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230161.